The Food and Drug Administration on Tuesday granted market clearance to Allergan's TrueTear Intranasal Tear Neurostimulator.
Here are three things to know.
1. The handheld device uses electrical stimulation to temporarily increase tear production in adult patients with dry eye.
2. Patients insert the device, which comes with disposable tips, into their nasal cavity to stimulate tear production.
3. TrueTear represents the first FDA-approved device to use neurostimulation to aid in tear production, according to Allergan.
More articles on supply chain:
3 things to know about National Prescription Drug Take Back Day
Pharmacist lobby group: PBMs prioritize profits over medication affordability
GHX recognizes 2017 healthcare supply chain leaders